Targeted therapy for hepatocellular carcinoma: Challenges and opportunities - Chen, Shuzhen; Cao, Qiqi; Wen, Wen; Wang, Hongyang (Cancer letters, 2019)
Keywords: Animals; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Biomarkers; Biomarkers, Tumor - antagonists & inhibitors; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Cancer therapies; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - enzymology; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - immunology; Clinical trials; Drug resistance; Drug Resistance, Neoplasm; Drug screening; Epidermal growth factor; FDA approval; Hepatocellular carcinoma; Hepatocellular carcinoma (HCC); Humans; Immunotherapy; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - enzymology; Liver Neoplasms - genetics; Liver Neoplasms - immunology; Medical prognosis; Molecular Targeted Therapy - adverse effects; Multi-kinase inhibitors (MKIs); Mutation; Precision medicine; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Signal Transduction; Stem cells; Tumor Microenvironment; FDA; c-KIT; PTEN; CXCR4; Drug resistance; ORR; EGFR; NF-κB; PI3K; Immunotherapy; VEGFR; PDGFR; mTOR; GPC3; GFRα; TICs; OS; FGF; EGF; VEGF; HGF; Hepatocellular carcinoma (HCC); TMB; HCC; Multi-kinase inhibitors (MKIs); MKI; AKT; FGFR; JAK; TANs; CAR-T; PDGF; SCF; LPCs; PD-1; LPC